Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Sorrento Therapeutics: Clinical Trials & FDA Approval Profile

Sorrento Therapeutics (Global / Institutional) sponsors 27 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 0 active protocols (0 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)74.1%
Median Closed Enrollment vs National (145 pts)97 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sorrento Therapeutics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)27
Active Pipeline (Recruiting Now)0 (0)
Completed vs Stopped Early3 / 20 (74.1%)
Median Closed Actual Enrollment97 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Sorrento Therapeutics Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI